PMCB — Pharmacyte Biotech Share News
0.000.00%
Last trade - 00:00Brief: PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
Brief: Pharmacyte Biotech Successfully Completes 24-Month Stability Study Of Its Clinical Trial Product Candidate
Brief: PharmaCyte Biotech Reports Third Quarter Financial Results And Operational Highlights
Brief: Pharmacyte Biotech- On Feb 24, Received Notification Letter From Nasdaq, Co Was No Longer In Compliance With Nasdaq’S Board Independence Rule
Brief: Pharmacyte Biotech Announces Genetic Stability Of Cytochrome P450 Gene And Site Of Integration
Brief: Pharmacyte Biotech Updates Status Of Investigational New Drug Application To FDA
Brief: Pharmacyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells
Brief: Pharmacyte Biotech Successfully Completes Cytochrome P450 Site Of Integration DNA Sequencing Assay
Brief: Pharmacyte Biotech Launches Malignant Ascites Program With Preclinical Study
Brief: PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation
Brief: Richard Abbe Reports 5.1% Stake In PharmaCyte Biotech Inc As Of Oct 27
Brief: PharmaCyte Biotech Inc Announces Encapsulation Material Does Not Alter Cellular Dna
Brief: PharmaCyte Biotech Inc Releases More Positive Results From FDA-Required Biocompatibility Tests
U.S. STOCKS ON THE MOVE-ForgeRock, IronNet, Dutch Bros
PharmaCyte Bio rises on biocompatibility results for cancer therapy
Brief: Pharmacyte Announces Positive Results Of Biocompatibility Study For FDA
Brief: PharmaCyte Biotech Expands Product Pipeline To Include Diabetes And Malignant Ascites Following $90-Million Capital Raise
Brief: PharmaCyte Biotech Says Registered Direct Offering Of $70 Million
PharmaCyte more than doubles in retail trading frenzy